Diabetes firm Vtv Therapeutics announces new CEO

Deepa Prasad joins Vtv Therapeutics from Westriver Group, replacing the former the president and CEO, who has overseen the development of oral drugs for diabetes and psoriasis.

Photo: Peter Hove Olesen/Politiken/Ritzau Scanpix

Vtv Therapeutics, a clinical-stage biopharmaceutical company, has announced a new company president and CEO, it reports in a press release.

Vtv Therapeutics, which developes orally administered treatments for type 1 diabetes and psoriasis, has announced that Stephen L. Holcombe, former company president and CEO, has retired. He is being replaced by Deepa Prasad, who joins shortly before the company initiates a crucial phase III trial with its leading candidate TTP399, which is a treatment for type 1 diabetes.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs